LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer BioSpace
LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial StreetInsider.com
LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abiraterone in Phase 3 PROfound Trial Business Wire
Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial WFMZ Allentown
Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial WFMZ Allentown
Global D-dimer Testing Market Forecast Revised in a Latest SMR Report as COVID-19 Estimate to Hold a Massive Impact on Sales in 2020 | Abbott, Beckman Coulter, Grifols, Becton Dickinson, Roche Owned
Comprehensive Report on Pulmonary Embolism Therapeutics Market 2020 | Size, Demand, Opportunities & Forecast To 2026 | Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Johnson and Johnson Services Inc., Genentech, Insera Therapeutics Red & Black Student Newspaper
Global Thrombosis Drugs Market : Industry Analysis and forecast (2019 to 2026) – By Drug Class, Disease Type, Distribution Channel, and Region Galus Australis
Global Upper Respiratory Tract Disorder Diagnostics and Therapeutics Market Industry Analysis Size, Share, regional outlook, growth and forecast 2018-2026 The Daily Chronicle